1 – 10 of 318
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
- Contribution to journal › Article
-
Mark
International Prophylaxis Study Group (IPSG) haemophilia joint MRI scale version 2.0
Lundin, Björn LU ; Bakeer, Nihal ; Dunn, Amy L. ; Gibikote, Sridhar ; Keshava, Shyamkumar N. ; Ljung, Rolf C.R. LU
; Papakonstantinou, Olympia
; Pergantou, Helen
; Strike, Karen
and Drygalski, Annette von
, et al.
(2024)
In Haemophilia
30(3).
p.862-864
- Contribution to journal › Letter
-
Mark
Origin of pathogenic variant and mosaicism in families with a sporadic case of haemophilia B
Mårtensson, Annika LU ; Letelier, Anna LU ; Manderstedt, Eric LU ; Glosli, Heidi and Ljung, Rolf LU
(2024)
In Haemophilia
30(3).
p.774-779
- Contribution to journal › Article
-
Mark
Low bleeding rates after intramuscular Covid-19 vaccination in patients with haemophilia and von Willebrand disease : Outcome data from the Swedish haemophilia registry
- Contribution to journal › Debate/Note/Editorial
-
Mark
Primary prophylaxis implementation and long-term joint outcomes in Swedish haemophilia A patients
- Contribution to journal › Article
-
Mark
Recombinant FVIII replacement products for haemophilia A : An updated valuation by indirect comparison measuring area under the curve
Persson, Sofie LU ; Fridhammar, Adam ; Carlsson, Katarina Steen LU
and Berntorp, Erik
LU
(2024)
In Haemophilia
30(5).
p.1230-1233
- Contribution to journal › Debate/Note/Editorial
- 2023
-
Mark
No difference in quality of life between persons with severe haemophilia A and B
- Contribution to journal › Article
-
Mark
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A
- Contribution to journal › Article
-
Mark
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A : Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
- Contribution to journal › Article
-
Mark
Primary prophylaxis in children with severe haemophilia A and B-Implementation over the last 20 years as illustrated in real-world data in the PedNet cohorts
Ljung, Rolf LU
; de Kovel, Marloes
and van den Berg, H Marijke
(2023)
In Haemophilia
29(2).
p.498-504
- Contribution to journal › Article